Latest News
BioMarin Pharmaceutical Inc.
- BioMarin Pharmaceutical Inc. Estimates – NASDAQ:BMRN
- BioMarin, Ascendis settle Yuviwel patent dispute with 20% US royalty
- BIOMARIN PHARMACEUTICAL INC (NASDAQ:BMRN) Screens as a Decent Value Stock on Cheap Forward Earnings
- Why is BioMarin Pharmaceutical stock gaining today?
- Biomarin Pharmaceutical Expects Q3 2026 Pre-Tax Charges Of $283 Million For Bought Ipr&D Expense
- BioMarin Appoints Cara Bauer as Chief People Officer
- BioMarin reports durable five-year outcomes with Pombiliti/Opfolda in late-onset Pompe disease
- BioMarin appoints Cara Bauer as new Chief People Officer, effective Oct 5, 2026.
- BioMarin Announces Five-Year Phase 3 Data for POMBILITI® (cipaglucosidase alfa-atga) + OPFOLDA® (miglustat) at World Muscle Society Annual Congress
- BioMarin and Profluent partner on AI-designed enzyme therapies
- BioMarin lays off 117 California workers to consolidate footprint
- Profluent Partners With BioMarin to Design Novel Medicines Using AI
Headlines from the last 30 days, linking to the original publishers. See all market news →